Rexin-G, a targeted genetic medicine for cancer

Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution

(2009) Jérôme Fayette et al.   ANTI-CANCER DRUGS

Novel Agents on the Horizon for Cancer Therapy

(2009) W. W. Ma et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Beyond RECIST: Molecular and functional imaging techniques for evaluation of response to targeted therapy

(2009) I.M.E. Desar et al.   CANCER TREATMENT REVIEWS

Phase I/II and Phase II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Chemotherapy-resistant Sarcoma and Osteosarcoma

(2009) Sant P Chawla et al.   MOLECULAR THERAPY

Advanced Phase I/II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Gemcitabine-resistant Metastatic Pancreatic Cancer

(2009) Sant P Chawla et al.   MOLECULAR THERAPY

Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

(2008) Paul A. Meyers et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Trial of a Pathotropic Retroviral Vector Expressing a Cytocidal Cyclin G1 Construct (Rexin-G) in Patients With Advanced Pancreatic Cancer

(2008) Evanthia Galanis et al.   MOLECULAR THERAPY

Selection of Response Criteria for Clinical Trials of Sarcoma Treatment

(2008) S. M. Schuetze et al.   ONCOLOGIST

New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways

(2008) H. Burris et al.   ONCOLOGIST

Metastatic Pancreatic Cancer 2008: Is the Glass Less Empty?

(2008) J. Nieto et al.   ONCOLOGIST

Radiologic Measurements of Tumor Response to Treatment: Practical Approaches and Limitations

(2008) Chikako Suzuki et al.   RADIOGRAPHICS